Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAF É).

CONCLUSIONS: Dupilumab+TCS significantly improved signs and symptoms of AD and QOL in adults with history of inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. No new safety signals were identified. This article is protected by copyright. All rights reserved.
PMID: 29193016 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - November 28, 2017 Category: Dermatology Authors: de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork M, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, Hultsch T, Chen Z, Pirozzi G, Graham NMH, Shumel B Tags: Br J Dermatol Source Type: research